However, mounting evidence suggests that GCs exert a dualistic immunomodulatory effect on the TME through the glucocorticoid receptor (GR) signaling pathway, potentially inhibiting tumor progression while also promoting immune evasion and metastasis. The gene discussed is NR3C1; the disease is neoplasm.